Valuation: Roche Holding AG

Market Cap 300B 374B 320B 274B 515B 35,776B 522B 3,541B 1,381B 17,972B 1,404B 1,373B 59,443B P/E 2026 *
20.9x
P/E 2027 * 18.6x
Enterprise Value 311B 387B 332B 284B 534B 37,073B 541B 3,669B 1,431B 18,623B 1,455B 1,423B 61,599B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 4.64x
Free-Float
88.78%
Yield 2026 *
2.66%
Yield 2027 * 2.72%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 374B
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +1.03%+4.97%+31.31%+53.20% 422.21B
Weighted average by Cap. +0.91%+5.09%+44.31%+72.55%

Financials

2026 *2027 *
Net sales 62.64B 78.16B 66.95B 57.34B 108B 7,478B 109B 740B 289B 3,757B 293B 287B 12,425B 65.47B 81.69B 69.97B 59.93B 112B 7,816B 114B 774B 302B 3,926B 307B 300B 12,986B
Net income 14.51B 18.1B 15.5B 13.28B 24.92B 1,732B 25.25B 171B 66.83B 870B 67.96B 66.48B 2,877B 16.33B 20.38B 17.46B 14.95B 28.06B 1,950B 28.43B 193B 75.25B 979B 76.52B 74.85B 3,240B
Net Debt 10.87B 13.56B 11.61B 9.95B 18.67B 1,297B 18.91B 128B 50.07B 652B 50.91B 49.8B 2,155B 4.02B 5.02B 4.3B 3.68B 6.91B 480B 7B 47.49B 18.52B 241B 18.83B 18.42B 797B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA